AJMC® in the Press, November 22, 2024

Author(s):

Key Takeaways

Geographic variability in Medicaid acceptance among allergists affects healthcare access and children's health outcomes related to allergies.
Video interviews from AJMC.com address cancer care gaps, medical distrust, and patient support beyond treatment.
Reducing avoidable emergency department visits for mental health could save $8.3 billion annually and improve patient outcomes.
FDA approval of xanomeline and trospium chloride marks a novel schizophrenia treatment targeting cholinergic receptors.
Senator Mike Lee's bill aims to eliminate costly switching study requirements for biosimilar interchangeability, potentially reducing pharmaceutical costs.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

A study entitled, “Geographic Variability of Medicaid Acceptance Among Allergists in the US,” published in the August 2024 issue of The American Journal of Managed Care^® (AJMC^®), was referenced in an article on Healio. According to the study, finding a provider who accepts a patient’s insurance was a barrier to accessing health care related to allergies, which could affect health outcomes in children with different allergies.

Two newsletters from NYU Langone Health referenced video interviews published on AJMC.com, the website of AJMC. The interviews, “Bridging Cancer Care Gaps and Overcoming Medical Distrust,” and “Uniting to Support Patients With Cancer Beyond Treatment,” featured interviews about topics covered during the Institute for Value-Based Medicine^® event, which highlighted cancer care including overcoming mistrust and providing support to patients.

An article from TechTarget referenced an article published on AJMC.com. The article, “Reducing ‘Avoidable’ ED Visits for Mental Health Could Cut Billions in Costs, Improve Patient Outcomes,” reported that reducing visits to the emergency department for patients with mental health or substance abuse–related that could be treated elsewhere would save approximately $8.3 billion per year.

An article from AJMC entitled, “First Schizophrenia Treatment Approved in Decades Targets Cholinergic Receptors,” was referenced in an article from Psychiatric Times^®. The article covered an FDA approval for xanomeline and trospium chloride capsules that marked the first treatment to target cholinergic receptors rather than dopamine receptors in adults with schizophrenia.

An article from Pharmacy Practice News referenced an article published by AJMC’s sister site, The Center for Biosimilars^®. The article, “Senator Reintroduces Biosimilar Red Tape Elimination Act,” reported on the reintroduction of a bill by Sen Mike Lee (R, Utah), which would “end costly and time-consuming switching study requirements for companies to obtain interchangeability for biosimilars.”